Lithium and Alzheimer’s Disease: New Research Links Low Brain Lithium to Memory Loss

New research has identified a surprising connection between lithium and Alzheimer’s disease, with potentially far-reaching implications for both early detection and disease-modifying therapy.

Lithium of a Different Color: A Surprising New Link to Alzheimer’s Disease

A surprising link between lithium and Alzheimer’s Disease has been discovered by scientists. Lithium—a mineral familiar to many of our readers from psychiatric treatments—has been known, for a long time, to naturally exist in our bodies. New research now suggests that having too little lithium in the brain may even be a triggering factor in Alzheimer’s disease.

Alzheimer’s Disease (AD) is marked by buildup of sticky protein clumps called amyloid plaques. The research showed that these plaques actually trap lithium, effectively stealing it away from brain cells. As a result, the brain becomes deficient in lithium. The researchers examined human brain tissues and found that lithium levels were noticeably lower even in very early stages of cognitive decline—before full-blown Alzheimer’s had developed. This suggests lithium loss is among the earliest changes in the disease’s onset.

The finding that lithium depletion precedes the observable onset of AD by a measurable interval is particularly significant from the standpoint of diagnosis: it raises the possibility that testing for lithium in cerebrospinal fluid or via neuroimaging could one day serve as early-warning indicators of Alzheimer’s risk, similarly to the role currently played by amyloid PET imaging and CSF tau measurements in preclinical AD detection.

Lithium Orotate in Mouse Models: Reversing Memory Deficits and Reducing Alzheimer-Type Brain Damage

To better understand the process, the team replicated these findings in mice. They found that mice with low lithium levels experienced faster accumulation of plaques, memory decline, and other Alzheimer-like changes. The scientists used an unusual lithium compound—lithium orotate—that doesn’t get trapped by plaques. When given to Alzheimer’s-model mice at very low doses, this compound reversed memory deficits and reduced Alzheimer-type brain damage.

Lithium orotate is structurally distinct from the lithium carbonate and lithium citrate formulations commonly used in psychiatric practice for the treatment of bipolar disorder. Its better bioavailability and apparent resistance to getting trapped in amyloid plaques — as demonstrated in this study — may make it a unique candidate for AD-focused clinical trials, though direct human evidence remains to be established.

What This Means for Alzheimer’s Prevention and Treatment: Cautious Optimism

Scientists not involved in the study point out that mouse models don't perfectly mirror human Alzheimer’s, so we can't yet assume the same effects happen in people. More human-based research and large-scale clinical trials are needed before drawing firm conclusions. If future human research confirms these findings, measuring lithium levels might help detect Alzheimer’s early. Further, low-dose lithium treatments could one day help to prevent or even reverse memory loss—an extraordinary shift from current symptom-managing approaches to potentially disease-altering therapies. ​

This research is part of intensified scientific interest in lithium’s neuroprotective properties. Multiple research groups have reported that long-term lithium exposure in patients treated for bipolar disorder is associated with reduced rates of dementia — a finding that lends increasing plausibility to lithium’s potential role in Alzheimer’s prevention. At Point Loma Clinic, we closely follow emerging neuropsychiatric research and integrate the latest evidence into our clinical practice. Contact our team to discuss how current psychiatric science may be relevant to your care.